RIYADH, KSA, Sept 18, 2026 – (ACN Newswire) – The Riyadh Global Medical Biotechnology Summit closed today as a significant success in its 4th edition and a clear declaration of the scale of Saudi Arabia’s aspiration in biotechnology. Over 3 days, more than 15,000 visitors from more than 57 nations and more than 200 speakers throughout more than 70 sessions saw that aspiration developed into more than 40 contracts, efforts, and statements with a combined stated worth of more than SAR 5 billion (USD 1.33 billion), up from more than USD 100 million in offer worth produced at the 2024 edition. Partners originated from Spain, China, Japan, Germany, the United States, South Korea, Denmark, and Malaysia to sign up with the Kingdom’s leading universities, proving ground, and producers at the Sofitel Riyadh Hotel and Convention Centre, where more than 120 sponsors and exhibitors filled 6,000 square meters of occasion area and more than 180 tactical conferences occurred.

More than 40 arrangements and statements, efforts, and statements worth more than SAR 5 billion( USD 1.33 billion)provided on every pillar of the Summit, from nationwide technique and guideline to financial investment, research study preparedness, and skill, with individuals from more than 57 nations in Riyadh.

The Summit opened on 14 September under the patronage of His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, and was inaugurated by His Royal Highness Prince Abdullah bin Bandar bin Abdulaziz, Minister of National Guard. His Excellency Prof. Bandar Alknawy MD, FRCPC CEO of the Ministry of National Guard Health Affairs (MNGHA) and President of King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), and King Abdullah International Medical Research Center (KAIMRC) Chairman of RGMBS, dealt with the opening event, explaining the Summit as a platform for advancing the National Biotechnology Strategy released by His Royal Highness the Crown Prince in January 2024, at a time of fast and significant discovery in the field. Her Royal Highness Princess Dr. Maha bint Mishari bin Abdulaziz Al Saud, Chief Executive Officer of the FII Institute, dealt with the opening event.

Her Royal Highness highlighted the function of capital, concepts, and long-lasting alliances in turning clinical developments into long lasting effect on mankind. She put the human function of the field at the center of the Summit’s work: extending not just the length of life however its quality, so that clients get more time, and much better time, with individuals they enjoy.

4 PILLARS, ONE NATIONAL MISSION

RGMBS 2026 was developed on 4 pillars under the style Building the Foundations of Biotechnology Excellence, with each pillar checked out through clinical, panel, and executive sessions.

• Governmental methods and regulative assistance. KAIMRC and the Ministry of Investment released BioSync. The one stop buy every biotech financier, combining the Kingdom’s whole life sciences ecosystem into a single, reliable platform. Regulators and researchers shared the phase throughout the program, culminating in a Day Three panel on guideline as a making it possible for clinical tool.
• Financial investment and financing. Vaccine Industrial Company validated that its human vaccine production center, a SAR 500 million financial investment throughout 42,000 square meters, is 85 percent total and is prepared to localize as much as 80 percent of the Kingdom’s important vaccine requirements. Sanabil Studio by Redesign Health signed with Telepath by Tahlili on AI and digital pathology, with a prospective financial investment of USD 3 million, and the Life Sciences Innovation Forum drew applications from more than 100 business, chose more than 25 for financial investment, and engaged 5 mutual fund ready to invest with a combined worth of more than USD 120 million.
• Research study and advancement preparedness. King Abdullah International Medical Research Center (KAIMRC) and Thermo Fisher Scientific revealed a Center of Excellence for Genomics, Proteomics, and Biobanking. The University Hospitals Program at the Council of Universities’ Affairs signed with Novo Nordisk to develop medical trial ability, consisting of earlier stage trials. KAIMRC likewise concurred research study cooperations with Olink in proteomics, Tiziana Life Sciences in immunomodulation and neuroimmunology, and Japan’s Chiyoda Corporation in plant-based peptide production for cancer treatment. King Saud University and BioMe of South Korea signed to develop a microbiome joint endeavor, the University of Hafr Al Batin partnered with BGI Group, and Najran University released the Najran Genomic Biobank Initiative.
• Structure abilities. KAIMRC signed with Rutgers University on a summertime school, master’s programs, and research study in expert system, and with LeapUp on training and capability structure. Princess Nourah bint Abdulrahman University and Cellenkos introduced a program to establish Saudi female skill in cell and gene treatment and biomanufacturing, and SVAX and Batterjee Medical College concurred certified biomanufacturing training with as much as 350 seats per cycle. King Saud University released 4 nationwide efforts, consisting of a yearly Saudi International Biotechnology Conference and the KSU BioHack hackathon.

3 DAYS ON THE MAIN STAGE

• The first day: The program opened with the National Biotechnology Strategy and a session on international collaboration with Dr. Steve Yang of WuXi AppTec, Mr. Alec Reynolds of Flagship Pioneering, and Prof. Ahmed Alaskar of KAIMRC, before turning to AI in biotechnology and multi-omics, consisting of Prof. Jin-Soo Kim of KAIST on mitochondrial DNA modifying beyond CRISPR.
• Day Two: Investment, immunology, and bioengineering took the phase, with Mr. Kasim Kutay of Novo Holdings on purchasing AI, Prof. Keith T. Flaherty, President of the American Association for Cancer Research, on cancer immunology, Astronaut Rayyanah Barnawi on the human body immune system in area, and Dr. Matthew H. Porteus of Stanford University on CRISPR-engineered cell-based drugs.
• Day Three: The last day concentrated on the biotechnology labor force and guideline, a closing keynote from Dr. Hyun-Young Park, Deputy Minister of the Korea National Institute of Health, ahead of the closing event.

“RGMBS 2026 has actually revealed the world what Saudi Arabia indicates when it states biotechnology is a nationwide objective. We called this edition for structures, and over 3 days those structures were laid in complete view: a vaccine plant nearing conclusion, a genomics center with Thermo Fisher, scientific trials with Novo Nordisk, and training for a brand-new generation of Saudi researchers, each with a called partner and a specified scope.

“Under the direction of our leadership and the National Biotechnology Strategy, the Kingdom is committed to leading this field for decades to come. We will measure that leadership by one standard above all: the difference it makes to the lives of patients and their families.”

H.E Bandar Alknawy MD, FRCPC CEO of the Ministry of National Guard Health Affairs (MNGHA) and President of KSAU-HS and KAIMRC Chairman of RGMBS.

RGMBS 2026 was arranged and monitored by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), and King Abdullah International Medical Research Center (KAIMRC), with the Ministry of Investment, Invest Saudi, and the FII Institute working as tactical partners. The dedications made in Riyadh advance the National Biotechnology Strategy, which targets a USD 34.6 billion contribution to non-oil GDP from biotechnology by 2040, and validate the Kingdom’s location at the leading edge of international biotechnology in the years ahead.

About The Riyadh Global Medical Biotechnology Summit

The Riyadh Global Medical Biotechnology Summit is the Kingdom of Saudi Arabia’s flagship platform for medical biotechnology, assembling the international clinical, financial investment, and policy neighborhoods in Riyadh. Organized and monitored by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by KAIMRC and KSAU-HS, the Summit advances the objectives of the National Biotechnology Strategy and supports the Kingdom’s introduction as a worldwide location for health development. The 4th edition occurred from 14 to 16 September 2026 in Riyadh. rgmbs.org

FOR FURTHER INFORMATION
Email: [email protected]
Telephone: +966 559 810 777

Subject: Press release summary